Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00201240 · ClinicalTrials.gov registry record · Phase 2
Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)
A Phase 2 study of Leukemia, Myelocytic, Acute, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 8
- Study locations
NCT00201240 is a Phase 2 study of Leukemia, Myelocytic, Acute that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 47 participants. The trial reports 8 study locations across 6 states.
The verdict
NCT00201240, a Phase 2 study of Leukemia, Myelocytic, Acute, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study is a single arm Phase II, multicenter trial. It is designed to determine whether the anticipated endpoints for a T cell depleted transplant arm of a planned prospective randomized trial comparing T cell depleted and unmodified hematopoietic allografts are likely to be achieved in a multicenter study conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN or Network). The study population is patients with acute myeloid leukemia (AML) in first or second morphologic complete remission. The enrollment is 45 patients. Based on published results of unmodified transplants from HLA-matched siblings applied to patients with AML in first or second morphologic complete remission, a significant improvement in results with a graft modified as specified in this protocol would be expected if disease-free survival (DFS) at 6 months was greater than 75%, the true incidence of transplant-related mortality at 1 year was less than 30%, and the DFS rate at 2 years was greater 70% for patients transplanted in first remission and less than 60% for patients transplanted in second remission. Additional secondary endpoints include the following: graft failure rate and incidences of acute grade II-IV and chronic graft-versus-host disease (GVHD). Additionally, the trial will have target specific doses of CD34+ progenitors and CD3+ T cells to be obtained following fractionation with the CliniMACS system. Based on the results of this trial, a Phase III trial comparing T cell depleted peripheral blood stem cell transplants (PBSCT) with unmanipulated bone marrow or unmanipulated PBSCT will be designed.
Conditions Studied
Interventions
- BIOLOGICAL CD34+ selection with CliniMACS device
Study Locations (8)
California
- City of Hope National Medical Center - Duarte
- University of California, San Francisco - San Francisco
Ohio
- University Hospitals of Cleveland/Case Western - Cleveland
- Ohio State/Arthur G. James Cancer Hospital - Columbus
Massachusetts
- Dana Farber Cancer Institute/Brigham & Women's Hospital - Boston
New York
- Memorial Sloan-Kettering Cancer Center - New York
Pennsylvania
- University of Pennsylvania Cancer Center - Philadelphia
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2005-06 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00201240
The ClinicalTrials.gov registry entry for NCT00201240 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Myelocytic, Acute appearing as the primary indexed condition, and to 1 intervention - of which CD34+ selection with CliniMACS device is the first listed.
NCT00201240 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Ohio, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00201240 about?
NCT00201240 is a clinical study titled "Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)". This study is a single arm Phase II, multicenter trial. It is designed to determine whether the anticipated endpoints for a T cell depleted transplant arm of a planned prospective randomized trial comparing T cell depleted and unmodified hematopoietic allografts are likely to be achieved in a multic...
What is the current status of trial NCT00201240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2005-06. Estimated completion is 2013-12.
What conditions does trial NCT00201240 study?
This clinical trial studies the following conditions: Leukemia, Myelocytic, Acute.
What interventions are being tested in trial NCT00201240?
The interventions under investigation include: CD34+ selection with CliniMACS device (BIOLOGICAL).
Who is sponsoring clinical trial NCT00201240?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00201240 being conducted?
This trial has 8 study locations across California, Massachusetts, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.